These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37566146)

  • 21. Biochemistry-informed design selects potent siRNAs against SARS-CoV-2.
    Houbron É; Mockly S; Rafasse S; Gros N; Muriaux D; Seitz H
    RNA Biol; 2023 Jan; 20(1):272-280. PubMed ID: 37272117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficient nanocarriers of siRNA therapeutics for cancer treatment.
    Subhan MA; Torchilin VP
    Transl Res; 2019 Dec; 214():62-91. PubMed ID: 31369717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo.
    Aigner A
    Appl Microbiol Biotechnol; 2007 Aug; 76(1):9-21. PubMed ID: 17457539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RNAi-based therapeutics and tumor targeted delivery in cancer.
    Kara G; Calin GA; Ozpolat B
    Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug delivery-mediated control of RNA immunostimulation.
    Nguyen DN; Chen SC; Lu J; Goldberg M; Kim P; Sprague A; Novobrantseva T; Sherman J; Shulga-Morskaya S; de Fougerolles A; Chen J; Langer R; Anderson DG
    Mol Ther; 2009 Sep; 17(9):1555-62. PubMed ID: 19584813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.
    De Paula D; Bentley MV; Mahato RI
    RNA; 2007 Apr; 13(4):431-56. PubMed ID: 17329355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. To accelerate the Zika beat: Candidate design for RNA interference-based therapy.
    Giulietti M; Righetti A; Cianfruglia L; Šabanović B; Armeni T; Principato G; Piva F
    Virus Res; 2018 Aug; 255():133-140. PubMed ID: 30031046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional nanostructures for effective delivery of small interfering RNA therapeutics.
    Hong CA; Nam YS
    Theranostics; 2014; 4(12):1211-32. PubMed ID: 25285170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses.
    Sajid MI; Moazzam M; Cho Y; Kato S; Xu A; Way JJ; Lohan S; Tiwari RK
    Mol Pharm; 2021 Jun; 18(6):2105-2121. PubMed ID: 33945284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted Delivery of siRNA Therapeutics using Ligand Mediated Biodegradable Polymeric Nanocarriers.
    Cho KS; Hong SJ; Ahn MH; Pal S; Choung PH; Sangshetti J; Arote RB
    Curr Pharm Des; 2018; 24(16):1788-1800. PubMed ID: 29962332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comprehensive update of siRNA delivery design strategies for targeted and effective gene silencing in gene therapy and other applications.
    Abosalha AK; Ahmad W; Boyajian J; Islam P; Ghebretatios M; Schaly S; Thareja R; Arora K; Prakash S
    Expert Opin Drug Discov; 2023 Feb; 18(2):149-161. PubMed ID: 36514963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic siRNA: principles, challenges, and strategies.
    Gavrilov K; Saltzman WM
    Yale J Biol Med; 2012 Jun; 85(2):187-200. PubMed ID: 22737048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short interfering RNA (siRNA): tool or therapeutic?
    Cejka D; Losert D; Wacheck V
    Clin Sci (Lond); 2006 Jan; 110(1):47-58. PubMed ID: 16336204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
    Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
    Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Where should siRNAs go: applicable organs for siRNA drugs.
    Ahn I; Kang CS; Han J
    Exp Mol Med; 2023 Jul; 55(7):1283-1292. PubMed ID: 37430086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.
    Davis ME; Zuckerman JE; Choi CH; Seligson D; Tolcher A; Alabi CA; Yen Y; Heidel JD; Ribas A
    Nature; 2010 Apr; 464(7291):1067-70. PubMed ID: 20305636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. siRNA release kinetics from polymeric nanoparticles correlate with RNAi efficiency and inflammation therapy via oral delivery.
    He C; Yue H; Xu L; Liu Y; Song Y; Tang C; Yin C
    Acta Biomater; 2020 Feb; 103():213-222. PubMed ID: 31812844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.